Triall
TRL
#2216
Triall (TRL) is a token of an end-to-end platform for data collection and research management. Triall solutions are designed to support any therapeutic area, research design, and research phase. The platform offers advanced integration capabilities with websites, mobile devices and wearables to support remote data collection and study management.
News about Triall
18 Jan 2024, 12:40
5 key areas for reporting & analytics in clinical trials 👩💻
eClinical tech continues to open up new avenues for reporting & analytics, promoting #clinicaltrial quality, efficiency & adaptability.
👇🧵Here are 5 critical areas for reporting & analytics enabled by #eClinical:
5 key areas for reporting & analytics in clinical trials .5 key areas for reporting & analytics in clinical trials 👩💻
eClinical tech continues to open up new avenues for reporting & analytics, promoting #clinicaltrial quality, efficiency & adaptability.
👇🧵Here are 5 critical areas for reporting & analytics enabled by #eClinical:
15 Jan 2024, 12:00
#TRLInsights - According to @TuftsCSDD , a typical Phase III #clinicaltrial conducted during 2016-2021 included an average of 25.8 endpoints.
This number is 37% higher compared to 2015, signalling a sharp increase in clinical trial complexity.
Source:
#TRLInsights - According to @TuftsCSDD , a typical Phase III #clinicaltrial conducted during 2016-2021 included an average of 25#TRLInsights - According to @TuftsCSDD , a typical Phase III #clinicaltrial conducted during 2016-2021 included an average of 25.8 endpoints.
This number is 37% higher compared to 2015, signalling a sharp increase in clinical trial complexity.
Source: https://t.co/T45Dv1Hzfb
08 Jan 2024, 11:53
#TRLInsights - 1 in 3 participants do not feel valued for their contribution to clinical research.
This can impact retention, satisfaction & overall adherence.
@TranscelerateB has therefore developed a best practices #Gratitude #Toolkit.
👉 Source:
#TRLInsights - 1 in 3 participants do not feel valued for their contribution to clinical research.#TRLInsights - 1 in 3 participants do not feel valued for their contribution to clinical research.
This can impact retention, satisfaction & overall adherence.
@TranscelerateB has therefore developed a best practices #Gratitude #Toolkit.
👉 Source: https://t.co/rWr1mjIrxZ
03 Jan 2024, 12:10
5 key automations in clinical trials 🤖
One of the most promising benefits of modern #eClinical solutions is their power to #automate manual, time-consuming, and error-prone study tasks.
👇🧵 Here are 5 promising areas for workflow automation in #clinicaltrials and #DeSci:
5 key automations in clinical trials.5 key automations in clinical trials 🤖
One of the most promising benefits of modern #eClinical solutions is their power to #automate manual, time-consuming, and error-prone study tasks.
👇🧵 Here are 5 promising areas for workflow automation in #clinicaltrials and #DeSci:
20 Dec 2023, 11:05
Future outlook: 5 key clinical trial trends in 2024 🧬
As we approach the end of the year it’s time to reflect and look ahead to what’s to come in 2024.
👇🧵 Here are 5 key industry trends that will be important for #clinicaltrials and #DeSci in 2024:
Future outlook: 5 key clinical trial trends in 2024.Future outlook: 5 key clinical trial trends in 2024 🧬
As we approach the end of the year it’s time to reflect and look ahead to what’s to come in 2024.
👇🧵 Here are 5 key industry trends that will be important for #clinicaltrials and #DeSci in 2024:
18 Dec 2023, 11:48
#TRLinsights - 90% of study participants indicate that receiving an act of appreciation increased satisfaction.
Incorporating items that show gratitude & engage patients throughout a clinical trial can result in improved retention & adherence.
Source:
#TRLinsights - 90% of study participants indicate that receiving an act of appreciation increased satisfaction.#TRLinsights - 90% of study participants indicate that receiving an act of appreciation increased satisfaction.
Incorporating items that show gratitude & engage patients throughout a clinical trial can result in improved retention & adherence.
Source: https://t.co/rWr1mjIrxZ
15 Dec 2023, 11:00
Partner Interview: CRO perspective on digitalisation🖥️
Embracing new technology is not just about adopting new tools. It’s fundamentally about having the right people & processes.
We spoke with Nick vd Bulk to talk about CR2O's digital transformation:
Partner Interview: CRO perspective on digitalisation. Embracing new technology is not just about adopting new tools.Partner Interview: CRO perspective on digitalisation🖥️
Embracing new technology is not just about adopting new tools. It’s fundamentally about having the right people & processes.
We spoke with Nick vd Bulk to talk about CR2O's digital transformation: https://t.co/CMSMElIGKa
13 Dec 2023, 12:51
#ProductSpotlight - Triall AI 🤖
Electronic health records (EHRs) have long remained untapped in clinical trials.
With our #AI tool, users can automatically structure & import #EHRs into their database, saving significant time & resources.
Info:
#DeSci
#ProductSpotlight - Triall AI. Electronic health records (EHRs) have long remained untapped in clinical trials.#ProductSpotlight - Triall AI 🤖
Electronic health records (EHRs) have long remained untapped in clinical trials.
With our #AI tool, users can automatically structure & import #EHRs into their database, saving significant time & resources.
Info: https://t.co/Z6iLrs4KXO
#DeSci
11 Dec 2023, 12:13
#TRLInsights - According to ISR, 89% of researchers think their EDC system does not fully meet their needs for executing decentralised trials.
Top unmet needs include better data integration and improved direct data capture from remote patients.
Source:
#TRLInsights - According to ISR, 89% of researchers think their EDC system does not fully meet their needs for executing decentr#TRLInsights - According to ISR, 89% of researchers think their EDC system does not fully meet their needs for executing decentralised trials.
Top unmet needs include better data integration and improved direct data capture from remote patients.
Source: https://t.co/vENwtbD7G2
08 Dec 2023, 12:44
Building the Clinical Insights Exchange 📺
Triall’s CIX platform vision aims to redefine the boundaries of data-informed #clinicalresearch and #DeSci.
This video providers a sneak peek into the #CIX catalogue, our #SSI wallet, and #TriallGPT, a chat agent that runs on #GPT4.
Building the Clinical Insights Exchange.Building the Clinical Insights Exchange 📺
Triall’s CIX platform vision aims to redefine the boundaries of data-informed #clinicalresearch and #DeSci.
This video providers a sneak peek into the #CIX catalogue, our #SSI wallet, and #TriallGPT, a chat agent that runs on #GPT4.
06 Dec 2023, 12:16
Being data-driven vs data-informed 🤖
The term ‘data-driven’ gets thrown around a lot these days, but can we really speak of #datadriven #clinicaltrials?
And what are the implications of #AI?
Let's take a closer look 👇🧵
Being data-driven vs data-informed.Being data-driven vs data-informed 🤖
The term ‘data-driven’ gets thrown around a lot these days, but can we really speak of #datadriven #clinicaltrials?
And what are the implications of #AI?
Let's take a closer look 👇🧵
04 Dec 2023, 12:43
#TRLInsights - Biotech is on the rise.
Since 2021, 60% of novel therapies approved by the @US_FDA are biotech products.
Moreover, global sales of #biotech products have consistently increased since 2018, surpassing $466 billion in 2022.
Source:
#TRLInsights - Biotech is on the rise. Since 2021, 60% of novel therapies approved by the @US_FDA are biotech products.#TRLInsights - Biotech is on the rise.
Since 2021, 60% of novel therapies approved by the @US_FDA are biotech products.
Moreover, global sales of #biotech products have consistently increased since 2018, surpassing $466 billion in 2022.
Source: https://t.co/T45Dv1Hzfb
29 Nov 2023, 12:47
Connecting Web3, AI & medical research 🤖
@a16zcrypto published a follow-on to its annual State of Crypto report.
It presents #Web3 adoption data & guiding principles for consumer protection, compliance & innovation.
Let’s dive into findings relevant to Triall & #DeSci 👇🧵
Connecting Web3, AI & medical research. @a16zcrypto published a follow-on to its annual State of Crypto report.Connecting Web3, AI & medical research 🤖
@a16zcrypto published a follow-on to its annual State of Crypto report.
It presents #Web3 adoption data & guiding principles for consumer protection, compliance & innovation.
Let’s dive into findings relevant to Triall & #DeSci 👇🧵
27 Nov 2023, 13:08
#TRLInsights - Patient organisations play an increasingly important role in healthcare.
For instance, they now provide input into 21% of drug health technology assessments globally, reaching as high as 52% in fields such as oncology in the EU.
Data:
#TRLInsights - Patient organisations play an increasingly important role in healthcare.#TRLInsights - Patient organisations play an increasingly important role in healthcare.
For instance, they now provide input into 21% of drug health technology assessments globally, reaching as high as 52% in fields such as oncology in the EU.
Data: https://t.co/Gd8dEqucLi
24 Nov 2023, 12:14
Should clinical trial participants own their data? 👩💻
Data ownership has been a topic of frequent debate among clinical trial stakeholders.
Let's dive into some recent developments 👇🧵
Should clinical trial participants own their data.Should clinical trial participants own their data? 👩💻
Data ownership has been a topic of frequent debate among clinical trial stakeholders.
Let's dive into some recent developments 👇🧵
20 Nov 2023, 12:45
#TRLInsights - Composite success rates in oncology trials have been trending down since 2015, falling to 3.5% in 2022.
This reflects the complexity of cancer research, which knows one of the lowest success rates among all therapeutic areas.
Source:
#TRLInsights - Composite success rates in oncology trials have been trending down since 2015, falling to 3. 5% in 2022.#TRLInsights - Composite success rates in oncology trials have been trending down since 2015, falling to 3.5% in 2022.
This reflects the complexity of cancer research, which knows one of the lowest success rates among all therapeutic areas.
Source: https://t.co/X09Qh1RUwX
16 Nov 2023, 12:02
Zooming in on novel trial designs 🔬
Novel trial designs, including umbrella, basket, master, and adaptive protocols, have seen a dramatic uptake from just 7.5% of new studies in 2010 to 17.0% in 2022.
What do these new study designs entail?
Let's dive right in 👇🧵
Zooming in on novel trial designs.Zooming in on novel trial designs 🔬
Novel trial designs, including umbrella, basket, master, and adaptive protocols, have seen a dramatic uptake from just 7.5% of new studies in 2010 to 17.0% in 2022.
What do these new study designs entail?
Let's dive right in 👇🧵
13 Nov 2023, 12:26
#TRLInsights - According to IQVIA, over 2,000 oncology products are currently under development.
71% of these products are coming from emerging biopharma companies (up from 45% a decade ago), signalling a decrease in reliance on Big Pharma.
Source:
#TRLInsights - According to IQVIA, over 2,000 oncology products are currently under development.#TRLInsights - According to IQVIA, over 2,000 oncology products are currently under development.
71% of these products are coming from emerging biopharma companies (up from 45% a decade ago), signalling a decrease in reliance on Big Pharma.
Source: https://t.co/X09Qh1RmHp
09 Nov 2023, 13:09
Decoding data-informed protocol development 🤖
In this article, we discuss how #RWD and historical #clinicaltrial data are successfully being used to make clinical trials more adaptable, cost-efficient, and patient-centric.
👉 Keep on reading:
Decoding data-informed protocol development.Decoding data-informed protocol development 🤖
In this article, we discuss how #RWD and historical #clinicaltrial data are successfully being used to make clinical trials more adaptable, cost-efficient, and patient-centric.
👉 Keep on reading: https://t.co/yf9MEaP9Ym
08 Nov 2023, 15:10
Triall listed in the State of European HealthTech 2023 market map by UK venture capital firm @AlbionVC 📢
The report includes a total of 998 companies across the #digitalpharma & #digitalcare domains.
👁 View the full map here:
Triall listed in the State of European HealthTech 2023 market map by UK venture capital firm @AlbionVC.Triall listed in the State of European HealthTech 2023 market map by UK venture capital firm @AlbionVC 📢
The report includes a total of 998 companies across the #digitalpharma & #digitalcare domains.
👁 View the full map here: https://t.co/bv88K9ecde
06 Nov 2023, 12:05
#TRLInsights - According to Tufts CSDD, the number of biotech products in late-stage clinical trials has quadrupled during the past decade.
594 novel #biotech products, 146 marketed products, and 192 #biosimilars are currently in Phase 3 studies.
Source:
#TRLInsights - According to Tufts CSDD, the number of biotech products in late-stage clinical trials has quadrupled during the p#TRLInsights - According to Tufts CSDD, the number of biotech products in late-stage clinical trials has quadrupled during the past decade.
594 novel #biotech products, 146 marketed products, and 192 #biosimilars are currently in Phase 3 studies.
Source: https://t.co/T45Dv1Hzfb
02 Nov 2023, 12:33
Moving beyond randomised controlled trials 🔍
In this article, we unpack the promise of external control arms, covering recent #FDA guidance on the design & conduct of externally controlled trials as well as two recent biopharma success stories.
👇 Link:
Moving beyond randomised controlled trials.Moving beyond randomised controlled trials 🔍
In this article, we unpack the promise of external control arms, covering recent #FDA guidance on the design & conduct of externally controlled trials as well as two recent biopharma success stories.
👇 Link: https://t.co/NAxxlWzb8j
30 Oct 2023, 12:39
#TRLInsights - According to IQVIA Institute, the past 5 years has seen a rising number of first-in-class medicines.
In 2022, 62% of launches included first-in-class therapies, reflecting the increasing availability of novel science for patients.
Source:
#TRLInsights - According to IQVIA Institute, the past 5 years has seen a rising number of first-in-class medicines.#TRLInsights - According to IQVIA Institute, the past 5 years has seen a rising number of first-in-class medicines.
In 2022, 62% of launches included first-in-class therapies, reflecting the increasing availability of novel science for patients.
Source: https://t.co/4g1orDbe2S
25 Oct 2023, 11:26
#TriallAMA - Did you catch our last session? 📺💬
In our last community AMA, Triall co-founder Ray talks about the promises of #DynamicConsent in clinical research and the enabling role of #blockchain and #SSI technologies.
👉 Check the full recording:
#TriallAMA - Did you catch our last session.#TriallAMA - Did you catch our last session? 📺💬
In our last community AMA, Triall co-founder Ray talks about the promises of #DynamicConsent in clinical research and the enabling role of #blockchain and #SSI technologies.
👉 Check the full recording: https://t.co/bL37G2y43E
23 Oct 2023, 11:07
#TRLInsights - According to the IQVIA institute, over 960 next-generation biotherapeutics are currently in development.
These include cell or gene therapies, gene editing, nucleotide and RNA interference, mRNA therapies, and RNA or DNA vaccines.
Source:
#TRLInsights - According to the IQVIA institute, over 960 next-generation biotherapeutics are currently in development.#TRLInsights - According to the IQVIA institute, over 960 next-generation biotherapeutics are currently in development.
These include cell or gene therapies, gene editing, nucleotide and RNA interference, mRNA therapies, and RNA or DNA vaccines.
Source: https://t.co/leAhfArEfw
18 Oct 2023, 11:12
Just in: research on key bottlenecks in clinical trials 🗞️
Researchers at Witten/Herdecke University conducted a critical path analysis to identify the most prominent bottlenecks in clinical operations and distill possible acceleration levers.
🔗 Link:
Just in: research on key bottlenecks in clinical trials.Just in: research on key bottlenecks in clinical trials 🗞️
Researchers at Witten/Herdecke University conducted a critical path analysis to identify the most prominent bottlenecks in clinical operations and distill possible acceleration levers.
🔗 Link: https://t.co/qb8UteUKfF
16 Oct 2023, 11:50
#TRLInsights - Over 75% of clinical trial protocols require at least one substantial amendment.
Protocol amendments are highly disruptive and represent the largest cause of unplanned delays & costs in #clinicaltrials.
Source:
#blockchainforhealth #TRL
#TRLInsights - Over 75% of clinical trial protocols require at least one substantial amendment.#TRLInsights - Over 75% of clinical trial protocols require at least one substantial amendment.
Protocol amendments are highly disruptive and represent the largest cause of unplanned delays & costs in #clinicaltrials.
Source: https://t.co/T45Dv1Hzfb
#blockchainforhealth #TRL
13 Oct 2023, 11:05
#TriallAMA - Announcing the winners 🏆📺💬
Wow! In our 16th #AMA session, the Triall #community submitted a record number of over 250 questions for the team.
Now, we’re thrilled to announce the winners...
🎙️ Rec:
👇 Winners:
#TriallAMA - Announcing the winners.#TriallAMA - Announcing the winners 🏆📺💬
Wow! In our 16th #AMA session, the Triall #community submitted a record number of over 250 questions for the team.
Now, we’re thrilled to announce the winners...
🎙️ Rec: https://t.co/bL37G2y43E
👇 Winners:
https://t.co/2RfkOe3EOw
12 Oct 2023, 12:12
Data-informed clinical research: zooming in on external control arms 🔍
Recent advancements in data science & technology have made way for a new virtual counterpart to the control group.
👇 Here we unpack the promises & limitations of this novel method:
Data-informed clinical research: zooming in on external control arms.Data-informed clinical research: zooming in on external control arms 🔍
Recent advancements in data science & technology have made way for a new virtual counterpart to the control group.
👇 Here we unpack the promises & limitations of this novel method: https://t.co/nacpDKBbQz
11 Oct 2023, 12:08
Did you catch our AMA? 📺💬
In our last #community #AMA, Triall co-founder Joost talks about how the utility of $TRL will evolve and expand over time with the introduction of new products & services.
👇 Check the full recording:
Did you catch our AMA.Did you catch our AMA? 📺💬
In our last #community #AMA, Triall co-founder Joost talks about how the utility of $TRL will evolve and expand over time with the introduction of new products & services.
👇 Check the full recording: https://t.co/qaaGiI2vOF
09 Oct 2023, 10:58
#TRLInsights - According to an industry-wide survey, 87% of sponsors and CROs are using or planning to use decentralised clinical trials (#DCTs) within 12 months.
Source:
#blockchainforhealth #TRL
#TRLInsights - According to an industry-wide survey, 87% of sponsors and CROs are using or planning to use decentralised clinica#TRLInsights - According to an industry-wide survey, 87% of sponsors and CROs are using or planning to use decentralised clinical trials (#DCTs) within 12 months.
Source: https://t.co/99efYHBPhX
#blockchainforhealth #TRL
05 Oct 2023, 12:03
And we’re live once again! 🚨📺💬
Tune in to session 16 of the Triall community AMA 👇
And we're live once again. Tune in to session 16 of the Triall community AMA.And we’re live once again! 🚨📺💬
Tune in to session 16 of the Triall community AMA 👇
04 Oct 2023, 10:53
Triall AMA - Session #16 📺💬
Are you joining us tomorrow?
At 2:00 UTC, Triall will host its 16th community #AMA on YouTube!
🏆 5 best questions win $50 in TRL.
🎙 AMA Guests:
- Hadil Es-Sbai, CEO
- Niels Klomp, CTO
- Joost Flach, Operations
- Raymond v.d. Waal, Partnerships
Triall AMA - Session #16. Are you joining us tomorrow. At 2:00 UTC, Triall will host its 16th community #AMA on YouTube.Triall AMA - Session #16 📺💬
Are you joining us tomorrow?
At 2:00 UTC, Triall will host its 16th community #AMA on YouTube!
🏆 5 best questions win $50 in TRL.
🎙 AMA Guests:
- Hadil Es-Sbai, CEO
- Niels Klomp, CTO
- Joost Flach, Operations
- Raymond v.d. Waal, Partnerships
02 Oct 2023, 11:23
#TRLInsights - 70% of research site staff believe conducting clinical trials has become much more difficult over the past 5 years.
The most commonly reported issues include staffing challenges, study budgets, and protocol complexity.
Source:
#TRLInsights - 70% of research site staff believe conducting clinical trials has become much more difficult over the past 5 year#TRLInsights - 70% of research site staff believe conducting clinical trials has become much more difficult over the past 5 years.
The most commonly reported issues include staffing challenges, study budgets, and protocol complexity.
Source: https://t.co/T45Dv1Hzfb
28 Sep 2023, 11:24
Introducing the Clinical Insights Exchange 📺
We're thrilled to give you a sneak peek into our CIX marketplace for privacy-friendly reuse of clinical trial data.
This video covers the #CIX catalogue, our #SSI wallet, and #TriallGPT, a chat agent that runs on the GPT-4 #LLM.
Introducing the Clinical Insights Exchange.Introducing the Clinical Insights Exchange 📺
We're thrilled to give you a sneak peek into our CIX marketplace for privacy-friendly reuse of clinical trial data.
This video covers the #CIX catalogue, our #SSI wallet, and #TriallGPT, a chat agent that runs on the GPT-4 #LLM.
26 Sep 2023, 11:13
Partner interview: CRO perspective on digital transformation.
Digitalisation requires the right people & processes.
We interviewed Nick van den Bulk, Head of Clinical Operations at CR2O, to talk about the company’s digital transformation journey.
👇Link
Partner interview: CRO perspective on digital transformation. Digitalisation requires the right people & processes.Partner interview: CRO perspective on digital transformation.
Digitalisation requires the right people & processes.
We interviewed Nick van den Bulk, Head of Clinical Operations at CR2O, to talk about the company’s digital transformation journey.
👇Link
25 Sep 2023, 11:01
#TRLInsights - According to @IQVIA_Institute , decentralised clinical trials can realise a 78% reduction in #patientrecruitment timelines, measured by time from first patient in to last patient in.
Source:
#DCT #clinicaltrials #eClinical
#TRLInsights - According to @IQVIA_Institute , decentralised clinical trials can realise a 78% reduction in #patientrecruitment#TRLInsights - According to @IQVIA_Institute , decentralised clinical trials can realise a 78% reduction in #patientrecruitment timelines, measured by time from first patient in to last patient in.
Source: https://t.co/Px4IT1TGDX
#DCT #clinicaltrials #eClinical
18 Sep 2023, 10:59
#TRLInsights - 80% of site staff are optimistic about the future operating environment for #clinicaltrials.
Optimism is significantly related to the degree to which site staff feels that sponsors request, value, and apply feedback from the site.
Source:
#TRLInsights - 80% of site staff are optimistic about the future operating environment for #clinicaltrials.#TRLInsights - 80% of site staff are optimistic about the future operating environment for #clinicaltrials.
Optimism is significantly related to the degree to which site staff feels that sponsors request, value, and apply feedback from the site.
Source: https://t.co/Fu4deP4T2d
14 Sep 2023, 10:49
Triall AMA - Announcing AMA #16 📺💬
On Oct 5 at 12:00 UTC, Triall will host its 16th community #AMA!
🎙 Guests
Hadil Es-Sbai, CEO
Niels Klomp, CTO
Joost Flach, Operations
Ray v.d. Waal, Partnerships
👉📬 Submit your questions & stand to win $50 in TRL:
Triall AMA - Announcing AMA #16. On Oct 5 at 12:00 UTC, Triall will host its 16th community #AMA. Guests. Hadil Es-Sbai, CEO.Triall AMA - Announcing AMA #16 📺💬
On Oct 5 at 12:00 UTC, Triall will host its 16th community #AMA!
🎙 Guests
Hadil Es-Sbai, CEO
Niels Klomp, CTO
Joost Flach, Operations
Ray v.d. Waal, Partnerships
👉📬 Submit your questions & stand to win $50 in TRL: https://t.co/EAw7CT0YgH
12 Sep 2023, 12:30
🗞️ @jmirpub published preprint of Triall's research paper with @MayoClinic physician Christopher McLeod.
The preprint marks the 1st publication in an article series on #blockchain-based dynamic consent in #patientcentric health data sharing & research.
👉https://t.co/d5ykYkqaLn
@jmirpub published preprint of Triall's research paper with @MayoClinic physician Christopher McLeod.🗞️ @jmirpub published preprint of Triall's research paper with @MayoClinic physician Christopher McLeod.
The preprint marks the 1st publication in an article series on #blockchain-based dynamic consent in #patientcentric health data sharing & research.
👉https://t.co/d5ykYkqaLn
11 Sep 2023, 11:32
#TRLInsights - 95% of sponsors & CROs have initiatives in place to address the operational challenges that resulted from the adoption of decentralised trials.
Top priorities include reducing site burden and improving data sharing & collaboration.
Source:
#TRLInsights - 95% of sponsors & CROs have initiatives in place to address the operational challenges that resulted from the ado#TRLInsights - 95% of sponsors & CROs have initiatives in place to address the operational challenges that resulted from the adoption of decentralised trials.
Top priorities include reducing site burden and improving data sharing & collaboration.
Source: https://t.co/HeZTvRj3kJ
04 Sep 2023, 11:09
#TRLInsights - Only 56% of sponsors report decentralised clinical trials (DCTs) had a positive impact on patient convenience & retention.
Main argument is that DCTs often introduce multiple patient-facing apps, thereby actually adding complexity.
Source:
#TRLInsights - Only 56% of sponsors report decentralised clinical trials (DCTs) had a positive impact on patient convenience & r#TRLInsights - Only 56% of sponsors report decentralised clinical trials (DCTs) had a positive impact on patient convenience & retention.
Main argument is that DCTs often introduce multiple patient-facing apps, thereby actually adding complexity.
Source: https://t.co/t8Y0eqEJdP
30 Aug 2023, 11:28
Triall at Nordic Blockchain Conference 🇩🇰
Triall co-founder Ray will be speaking at a panel discussion during the largest #Web3 community event in the Nordics.
🎙️ Unchained Health: Practical Lessons from the Intersection of Blockchain and Health
⏰ Sep 6, 13:30-14:15 CEST
Triall at Nordic Blockchain Conference.Triall at Nordic Blockchain Conference 🇩🇰
Triall co-founder Ray will be speaking at a panel discussion during the largest #Web3 community event in the Nordics.
🎙️ Unchained Health: Practical Lessons from the Intersection of Blockchain and Health
⏰ Sep 6, 13:30-14:15 CEST
28 Aug 2023, 10:56
TRLInsights - 78% of clinical research professionals trust that Risk-Based Quality Management (#RBQM) will improve #clinicaltrial quality.
A majority of respondents say a lack of cross-functional awareness is the top adoption barrier for RBQM.
Source:
TRLInsights - 78% of clinical research professionals trust that Risk-Based Quality Management (#RBQM) will improve #clinicaltriaTRLInsights - 78% of clinical research professionals trust that Risk-Based Quality Management (#RBQM) will improve #clinicaltrial quality.
A majority of respondents say a lack of cross-functional awareness is the top adoption barrier for RBQM.
Source: https://t.co/T45Dv1Hzfb
22 Aug 2023, 12:14
Wrapped up an electrifying day in Düsseldorf at #DDD23! 🚀
Triall co-founder Ray took the stage during the event’s startup #pitch competition and we presented our Clinical Insights Exchange (#CIX) prototype at a dedicated #demo booth.
Shoutout to @digihub_de for this event!
Wrapped up an electrifying day in Düsseldorf at #DDD23.Wrapped up an electrifying day in Düsseldorf at #DDD23! 🚀
Triall co-founder Ray took the stage during the event’s startup #pitch competition and we presented our Clinical Insights Exchange (#CIX) prototype at a dedicated #demo booth.
Shoutout to @digihub_de for this event!
21 Aug 2023, 11:51
#TRLInsights - 94% of technology vendors list risk aversion as an implementation barrier for patient-facing technologies in clinical trials.
Early partnerships, customer engagement & experimentation were mentioned as key implementation enablers.
Source:
#TRLInsights - 94% of technology vendors list risk aversion as an implementation barrier for patient-facing technologies in clin#TRLInsights - 94% of technology vendors list risk aversion as an implementation barrier for patient-facing technologies in clinical trials.
Early partnerships, customer engagement & experimentation were mentioned as key implementation enablers.
Source:
https://t.co/YqbM9MV3Gl
16 Aug 2023, 11:00
Meet us at Digital Demo Day 🇩🇪
Tomorrow, Triall co-founder Ray will participate in the startup pitch competition of #DDD23 in Germany.
Next to pitching we’ll be hosting a booth to demo the prototype of our Clinical Insights Exchange (#CIX).
Also present? Visit us at booth A9a!
Meet us at Digital Demo Day.Meet us at Digital Demo Day 🇩🇪
Tomorrow, Triall co-founder Ray will participate in the startup pitch competition of #DDD23 in Germany.
Next to pitching we’ll be hosting a booth to demo the prototype of our Clinical Insights Exchange (#CIX).
Also present? Visit us at booth A9a!
14 Aug 2023, 11:01
#TRLInsights - 42% of clinical trial terminations across 2022 occurred in phase 2 studies.
The most prominent reasons for termination were business/strategic decisions and low accrual rates.
Source:
#blockchainforhealth #TRL
#TRLInsights - 42% of clinical trial terminations across 2022 occurred in phase 2 studies.#TRLInsights - 42% of clinical trial terminations across 2022 occurred in phase 2 studies.
The most prominent reasons for termination were business/strategic decisions and low accrual rates.
Source: https://t.co/03uNcvltK7
#blockchainforhealth #TRL
09 Aug 2023, 12:08
Staking pool closing soon 💎
Our $TRL #staking pool is closing in 2 days!
👉 Join our 8% APR pool on #BSC at
New to $TRL staking?
✅ Whitelist yourself:
📋 Read the guide:
#blockchainforhealth #TRL
Staking pool closing soon. Our $TRL #staking pool is closing in 2 days. Join our 8% APR pool on #BSC at. New to $TRL staking.Staking pool closing soon 💎
Our $TRL #staking pool is closing in 2 days!
👉 Join our 8% APR pool on #BSC at https://t.co/NyM5Li4XjX
New to $TRL staking?
✅ Whitelist yourself: https://t.co/sCHML0vDPn
📋 Read the guide: https://t.co/wwU8d6uVVp
#blockchainforhealth #TRL
07 Aug 2023, 11:03
#TRLInsights - 57% of clinical trials initiated in 2022 were conducted by non-industry sponsors such as academic hospitals & institutions.
These studies are predominantly single-country trials based in the US or China.
Source:
#blockchainforhealth #TRL
#TRLInsights - 57% of clinical trials initiated in 2022 were conducted by non-industry sponsors such as academic hospitals & ins#TRLInsights - 57% of clinical trials initiated in 2022 were conducted by non-industry sponsors such as academic hospitals & institutions.
These studies are predominantly single-country trials based in the US or China.
Source: https://t.co/03uNcvltK7
#blockchainforhealth #TRL
Shownews
10
50
100